Preclinical models to study patient-derived circulating tumor cells and metastasis

Trends Cancer. 2023 Apr;9(4):355-371. doi: 10.1016/j.trecan.2023.01.004. Epub 2023 Feb 8.

Abstract

Circulating tumor cells (CTCs) that are detached from the tumor can be precursors of metastasis. The majority of studies focus on enumeration of CTCs from patient blood to predict recurrence and therapy outcomes. Very few studies have managed to expand CTCs to investigate their functional dynamics with respect to genetic changes, tumorigenic potential, and response to drug treatment. A growing amount of evidence based on successful CTC expansion has revealed novel therapeutic targets that are associated with the process of metastasis. In this review, we summarize the successes, challenges, and limitations that collectively contribute to the better understanding of metastasis using patient-derived CTCs as blood-borne seeds of metastasis. The roadblocks and future avenues to move CTC-based scientific discoveries forward are also discussed.

Keywords: circulating tumor cells; humanized mouse models of cancer; metastasis; patient-derived xenografts; preclinical models.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor
  • Carcinogenesis
  • Humans
  • Neoplastic Cells, Circulating* / pathology

Substances

  • Biomarkers, Tumor